Sökning: WFRF:(Karrasch M)
> (2020-2022)
> Blennow Kaj 1958 >
ASIC-E4: Interplay ...
ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease - Study Protocol and Baseline Characteristics
-
- Snellman, Anniina (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
Ekblad, L. L. (författare)
-
Koivumaeki, M. (författare)
-
visa fler...
-
Lindgren, N. (författare)
-
Tuisku, J. (författare)
-
Peraelae, M. (författare)
-
Kallio, L. (författare)
-
Lehtonen, R. (författare)
-
Saunavaara, V. (författare)
-
Saunavaara, J. (författare)
-
Oikonen, V. (författare)
-
Aarnio, R. (författare)
-
Loyttyniemi, E. (författare)
-
Parkkola, R. (författare)
-
Karrasch, M. (författare)
-
- Zetterberg, Henrik, 1973 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
- Blennow, Kaj, 1958 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
Rinne, J. O. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2022-02-09
- 2022
- Engelska.
-
Ingår i: Frontiers in Neurology. - : Frontiers Media SA. - 1664-2295. ; 13
- Relaterad länk:
-
https://www.frontier...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.3...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background:& nbsp;Detailed characterization of early pathophysiological changes in preclinical Alzheimer's disease (AD) is necessary to enable development of correctly targeted and timed disease-modifying treatments. ASIC-E4 study ( "Beta-Amyloid, Synaptic loss, Inflammation and Cognition in healthy APOE epsilon 4 carriers ") combines state-of-the-art neuroimaging and fluid-based biomarker measurements to study the early interplay of three key pathological features of AD, i.e., beta-amyloid (A beta) deposition, neuroinflammation and synaptic dysfunction and loss in cognitively normal volunteers with three different levels of genetic (APOE-related) risk for late-onset AD.& nbsp;Objective:& nbsp;Here, our objective is to describe the study design, used protocols and baseline demographics of the ASIC-E4 study.& nbsp;Methods/Design:& nbsp;ASIC-E4 is a prospective observational multimodal imaging study performed in Turku PET Centre in collaboration with University of Gothenburg. Cognitively normal 60-75-year-old-individuals with known APOE epsilon 4/epsilon 4 genotype were recruited via local Auria Biobank (Turku, Finland). Recruitment of the project has been completed in July 2020 and 63 individuals were enrolled to three study groups (Group 1: APOE epsilon 4/epsilon 4, N = 19; Group 2: APOE epsilon 4/epsilon 3, N = 22; Group 3: APOE epsilon 3/epsilon 3, N = 22). At baseline, all participants will undergo positron emission tomography imaging with tracers targeted against A beta deposition (C-11-PIB), activated glia (C-11-PK11195) and synaptic vesicle glycoprotein 2A (C-11-UCB-J), two brain magnetic resonance imaging scans, and extensive cognitive testing. In addition, blood samples are collected for various laboratory measurements and blood biomarker analysis and cerebrospinal fluid samples are collected from a subset of participants based on additional voluntary informed consent. To evaluate the predictive value of the early neuroimaging findings, neuropsychological evaluation and blood biomarker measurements will be repeated after a 4-year follow-up period.& nbsp;Discussion:& nbsp;Results of the ASIC-E4 project will bridge the gap related to limited knowledge of the synaptic and inflammatory changes and their association with each other and A beta in "at-risk " individuals. Thorough in vivo characterization of the biomarker profiles in this population will produce valuable information for diagnostic purposes and future drug development, where the field has already started to look beyond A beta.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Nyckelord
- Alzheimer's disease
- APOE
- preclinical
- biomarker
- beta-amyloid
- TSPO
- (18 kDa translocator protein)
- SV2A ligand
- neuroinflammation
- microglial activation
- apolipoprotein-e
- total score
- a-beta
- apoe
- accumulation
- association
- performance
- burden
- Neurosciences & Neurology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Snellman, Anniin ...
-
Ekblad, L. L.
-
Koivumaeki, M.
-
Lindgren, N.
-
Tuisku, J.
-
Peraelae, M.
-
visa fler...
-
Kallio, L.
-
Lehtonen, R.
-
Saunavaara, V.
-
Saunavaara, J.
-
Oikonen, V.
-
Aarnio, R.
-
Loyttyniemi, E.
-
Parkkola, R.
-
Karrasch, M.
-
Zetterberg, Henr ...
-
Blennow, Kaj, 19 ...
-
Rinne, J. O.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Neurovetenskaper
- Artiklar i publikationen
-
Frontiers in Neu ...
- Av lärosätet
-
Göteborgs universitet